WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530647
CAS#: 127692-13-1
Description: CGI-17341 is an orally active representative of the 5-nitroimidazole series of antimicrobial agents. At concentrations ranging from 0.1 to 0.3 micrograms/ml, CGI 17341 inhibited the drug-susceptible and multi-drug-resistant strains of Mycobacterium tuberculosis. CGI 17341 had no cross-resistance with isoniazid, rifampin, streptomycin, or ethambutol. CGI 17341 is a promising and novel antituberculosis compound with potent in vitro and in vivo activities.
Hodoodo Cat#: H530647
Name: CGI-17341
CAS#: 127692-13-1
Chemical Formula: C7H9N3O3
Exact Mass: 183.06
Molecular Weight: 183.167
Elemental Analysis: C, 45.90; H, 4.95; N, 22.94; O, 26.20
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CGI-17341; CGI 17341; CGI17341.
IUPAC/Chemical Name: 2,3-Dihydro-2-ethyl-6-nitroimidazo(2,1-b)oxazole
InChi Key: AEKVVFWCBKEYSC-UHFFFAOYSA-N
InChi Code: InChI=1S/C7H9N3O3/c1-2-5-3-9-4-6(10(11)12)8-7(9)13-5/h4-5H,2-3H2,1H3
SMILES Code: O=[N+](C1=CN2C(OC(CC)C2)=N1)[O-]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 183.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, Norton JE, Daniels L,
Dick T, Pang SS, Barry CE 3rd. Identification of a nitroimidazo-oxazine-specific
protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl
Acad Sci U S A. 2006 Jan 10;103(2):431-6. Epub 2005 Dec 30. PubMed PMID:
16387854; PubMed Central PMCID: PMC1326169.
2: Tomioka H. [Prospects for development of new antituberculous drugs]. Kekkaku.
2002 Aug;77(8):573-84. Japanese. PubMed PMID: 12235850.
3: Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH,
Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. A
small-molecule nitroimidazopyran drug candidate for the treatment of
tuberculosis. Nature. 2000 Jun 22;405(6789):962-6. PubMed PMID: 10879539.
4: Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W.
In vitro and in vivo activities of the nitroimidazole CGI 17341 against
Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1993 Feb;37(2):183-6.
PubMed PMID: 8452346; PubMed Central PMCID: PMC187635.
